Kamada (KMDA) Downgraded by Zacks Investment Research

Zacks Investment Research cut shares of Kamada (NASDAQ:KMDA) from a buy rating to a hold rating in a research report released on Friday morning, Zacks.com reports.

According to Zacks, “Kamada Ltd. is a biopharmaceutical company. It develops, produces and markets therapeutics based on chromatographic purification technology. The company offers bio-therapeutics for specialty proteins, specific immunoglobulins and other prescription medicines. Kamada Ltd. is headquartered in Ness Ziona, Israel. “

Separately, HC Wainwright restated a buy rating and set a $11.00 price target on shares of Kamada in a report on Thursday, February 14th.

Shares of NASDAQ:KMDA opened at $5.72 on Friday. Kamada has a 1 year low of $4.50 and a 1 year high of $6.70. The stock has a market cap of $230.92 million, a P/E ratio of 10.43 and a beta of 1.15. The company has a current ratio of 4.70, a quick ratio of 3.46 and a debt-to-equity ratio of 0.01.

Kamada (NASDAQ:KMDA) last announced its quarterly earnings results on Tuesday, February 12th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.15 by $0.29. Kamada had a return on equity of 22.74% and a net margin of 19.48%. The company had revenue of $48.21 million for the quarter. On average, analysts expect that Kamada will post 0.47 earnings per share for the current fiscal year.

A number of institutional investors have recently bought and sold shares of KMDA. Renaissance Technologies LLC boosted its position in Kamada by 17.9% during the 3rd quarter. Renaissance Technologies LLC now owns 548,100 shares of the biotechnology company’s stock valued at $3,398,000 after acquiring an additional 83,200 shares in the last quarter. Vanguard Group Inc. boosted its position in Kamada by 11.6% during the 3rd quarter. Vanguard Group Inc. now owns 583,797 shares of the biotechnology company’s stock valued at $3,620,000 after acquiring an additional 60,866 shares in the last quarter. Vanguard Group Inc boosted its position in Kamada by 11.6% during the 3rd quarter. Vanguard Group Inc now owns 583,797 shares of the biotechnology company’s stock valued at $3,620,000 after acquiring an additional 60,866 shares in the last quarter. ETF Managers Group LLC bought a new stake in Kamada during the 4th quarter valued at approximately $263,000. Finally, Ramsey Quantitative Systems boosted its position in Kamada by 341.7% during the 4th quarter. Ramsey Quantitative Systems now owns 36,154 shares of the biotechnology company’s stock valued at $181,000 after acquiring an additional 27,969 shares in the last quarter. 12.65% of the stock is currently owned by institutional investors and hedge funds.

Kamada Company Profile

Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates through two segments, Proprietary Products and Distribution. The company offers respiratory products, including Glassia for use in augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin (AAT) deficiency.

Recommended Story: Certificate of Deposit (CD)

Get a free copy of the Zacks research report on Kamada (KMDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.